US 11124768
Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
granted A61KA61K2239/38A61K40/19
Quick answer
US patent 11124768 (Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response) held by Northwest Biotherapeutics, Inc. expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Northwest Biotherapeutics, Inc.
- Grant date
- Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2239/38, A61K40/19, A61K40/24, A61K40/42